Xenetic Biosciences Balance Sheet Health
Financial Health criteria checks 6/6
Xenetic Biosciences has a total shareholder equity of $7.0M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $8.0M and $1.0M respectively.
Key information
0%
Debt to equity ratio
US$0
Debt
| Interest coverage ratio | n/a |
| Cash | US$6.84m |
| Equity | US$7.04m |
| Total liabilities | US$1.01m |
| Total assets | US$8.05m |
Recent financial health updates
Recent updates
Most Shareholders Will Probably Find That The Compensation For Xenetic Biosciences, Inc.'s (NASDAQ:XBIO) CEO Is Reasonable
Dec 15
Why We Think Xenetic Biosciences, Inc.'s (NASDAQ:XBIO) CEO Compensation Is Not Excessive At All
Dec 01Xenetic Biosciences reports Q2 results
Aug 12Xenetic Biosciences, VolitionRx collaborate to develop cell therapies to treat cancer
Aug 02Xenetic inks clinical manufacturing contract with Catalent
Jul 07Xenetic Biosciences reports Q3 results
Nov 13Financial Position Analysis
Short Term Liabilities: XBIO's short term assets ($7.0M) exceed its short term liabilities ($1.0M).
Long Term Liabilities: XBIO has no long term liabilities.
Debt to Equity History and Analysis
Debt Level: XBIO is debt free.
Reducing Debt: XBIO had no debt 5 years ago.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: XBIO has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: XBIO has sufficient cash runway for 1.8 years if free cash flow continues to grow at historical rates of 4.5% each year.
Discover healthy companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/26 02:24 |
| End of Day Share Price | 2024/12/24 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Xenetic Biosciences, Inc. is covered by 4 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Joseph Pantginis | H.C. Wainwright & Co. |
| Kevin DeGeeter | Ladenburg Thalmann & Company |
| Rahul Jasuja | NOBLE Capital Markets, Inc. |